Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study
In patients with unresectable and TACE-unsuitable early-to-intermediate-stage HCC who met the drug-off criteria, significantly improved RFS and OS were observed compared those who did not meet the criteria. However, further validation studies are required to confirm the utility of the criteria.
Authors
- Joji Tani (ORCID: https://orcid.org/0000-0001-8801-2505)
- Ippei Matsumoto (ORCID: https://orcid.org/0000-0003-3965-3693)
- Kazuhito Kawata (ORCID: https://orcid.org/0000-0002-4986-8578)
- Kaoru Tsuchiya (ORCID: https://orcid.org/0000-0003-0436-5915)
- Takeshi Hatanaka (ORCID: https://orcid.org/0000-0003-3656-285X)
- Naoshi Nishida (ORCID: https://orcid.org/0000-0002-9111-5668)
- Masatoshi Kudo (ORCID: https://orcid.org/0000-0002-4102-3474)
- Hiroshi Ida (ORCID: https://orcid.org/0000-0002-0690-8218)
- Tetsu Tomonari (ORCID: https://orcid.org/0000-0002-8484-9866)
- Atsushi Takebe (ORCID: https://orcid.org/0009-0008-0506-6208)
- Masahiro Morita (ORCID: https://orcid.org/0000-0002-8627-084X)
- Atsushi Hiraoka (ORCID: https://orcid.org/0000-0003-1989-0480)
- Takashi Kumada (ORCID: https://orcid.org/0000-0003-2211-495X)
- Masaaki Hidaka (ORCID: https://orcid.org/0000-0001-8191-6405)
- Chikara Ogawa (ORCID: https://orcid.org/0000-0002-4534-6692)
- Yasunori Minami (ORCID: https://orcid.org/0000-0001-7146-5954)
- Namiki Izumi (ORCID: https://orcid.org/0000-0002-0055-8229)
- Toshifumi Tada (ORCID: https://orcid.org/0000-0002-0976-6761)
- Atsushi Naganuma (ORCID: https://orcid.org/0000-0003-0663-0102)
- Hidekatsu Kuroda (ORCID: https://orcid.org/0000-0002-1471-1087)
- Toru Ishikawa (ORCID: https://orcid.org/0000-0002-5470-9694)
- Kazuomi Ueshima (ORCID: https://orcid.org/0000-0002-7577-5789)
- Tomoko Aoki (ORCID: https://orcid.org/0000-0002-9950-4553)
- Masayuki Kurosaki (ORCID: https://orcid.org/0000-0001-7016-8931)
- Satoru Kakizaki (ORCID: https://orcid.org/0000-0003-0224-7093)
- Masahiro Takita
- Satoru Hagiwara
- Noriaki Nakamura
- Hirokazu Chishina
Institutions
- Iwate Medical University (JP)
- Kagawa University (JP)
- Hamamatsu University School of Medicine (JP)
- Takamatsu Red Cross Hospital (JP)
- Eiju General Hospital (JP)
- Saiseikai Niigata Daini Hospital (JP)
- National Hospital Organization Takasaki Medical Center (JP)
- Gunma Saiseikai Maebashi Hospital (JP)
- Himeji Red Cross Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- Musashino Red Cross Hospital (JP)
- Nagasaki University (JP)
- Gifu Kyoritsu University (JP)
- Kindai University (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Journal of Gastroenterology
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1007/s00535-025-02233-z
- Citations
- 6
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 7.93
Funders
- University of Tokyo
- Japan Society for the Promotion of Science